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D.R. Bereiter, D.H. Mintz. and T.E. Starzl 
REPORTS of short-term 1 and prolonged:!-5 insulin in-
dependence following human islet allotransplanta-
tion indicate that it is possible to replace the endocrine 
function of the pancreas by an islet transplant in humans. 
This article discusses our initial experience with islet 
isolation and intrahepatic allotransplantation in 18 pa-
tients. 
MATERIALS AND METHODS 
Nineteen mtrahepatic islet allografts were performed in 18 pa-
tients. In group I. nine patients aged 8 to 58 years underwent 
(ombined liver-Islet allotransplantation following upper-abdomi-
nal exenteration for tumors too extensive to be removed with less 
drastic procedures.b•7 Preliminary results on these patients have 
been reponed previouslyK~ In group 2. three type I diabetic 
patients aged 22 to 56 years received a combined liver-islet 
allograft. The indications for liver transplantation were cirrhosis 
secondary to hepatitis C. alcoholic cirrhosis. and cryptogenic 
cirrhosis. All patients had an absent C-peptide response to gluca-
gon or Sustacal challenge test. In group 3. six patients aged 28 to 
42 years received seven combined cadaveric kidney-islet grafts 
(one retransplant) for end-stage renal disease secondary to type I 
diabetes mellitus. 
The human islets were obtained by a modificationM of the 
automated method for human islet isolation. ~ The preparation was 
Infused into the ponal vein catheter over 20 to 30 minutes. 
Immunosuppression was with FK-506 (group Il and FK-506 plus 
steroids (groups 2 and 3), Supplementary sterOIds or OKT3 was 
given if rejection was suspected clinically or diagnosed by biopsy. 
RESULTS AND DISCUSSION 
Patients in groups 2 and 3 received a number of islets that 
was significantly higher (P < .05) compared to the cluster-
islet patients of group I (data not shown). In group I. six 
patients did not require insulin for 5 to over 16 months. 
The first patient. who received the islet allograft on Janu-
ary 10. 1990. is still insulin independent over 16 months 
postoperatively. Since the first report.; two patients died 
for cancer recurrence. In group 2. one patient is alive 7 
months after transplantation. She had a 100% positive 
cytotoxic crossmatch and a rejection episode during the 
first postoperative week. Approximately an 80% decrease 
in her insulin requirement was observed over the first 6 
postoperative months (from 70 to 15 units of insulin per 
day). HbAlc has been within the normal range «5.9%). In 
addition. C-peptide response (>2 pmollL) to Sustacal 
challenge tests 2. 3. and 6 months after transplantation has 
progressively improved. The second patient. who died 6 
months after transplantation from hepatitis B and sepsis. 
also demonstrated significant islet function (basal and 
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stimulated C-peptide levels of 0.76 and 1.59 pmol/L. re-
spectively). A third patient died 36 hours following com-
bined liver-islet allotransplantation from primary nonfunc-
tion of the liver due to humoral (hyperacute) rejection. The 
crossmatch was 100% positive. In group 3. none of the 
patients became insulin independent. One patient died 
from aspiration pneumonia 5 days following surgery. 
In the present report. prolonged (5 to > 16 months) 
insulin independence was observed in six patients who 
underwent upper-abdominal exenteration and liver-islet 
replacement.: Four of them received islets from two 
donors. In contrast. in our expenence none of the type I 
diabetic patients who received either a liver-islet or a 
kidney-islet allograft are insulin independent. Although 
our best result in type I diabetic patients was obtained in a 
case of positive crossmatch (100%). we currently consider 
a positive cross match as an absolute contraindication to 
human islet allotransplantation because of the increased 
risk of morbidity and mortality in this group. 
In conclusion. our results indicate that rejection is still a 
major factor limiting the clinical application of islet trans-
plantation in patients with type I diabetes mellitus. al-
though other factors. such as steroid treatment. may 
contribute to impaired islet engraftment and/or function. 
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